Cevimeline hydrochloride - Generic Drug Details

What are the generic sources for cevimeline hydrochloride and what is the scope of freedom to operate?

Cevimeline hydrochloride is the generic ingredient in two branded drugs marketed by Apotex Inc, Aurobindo Pharma, Bionpharma, Hikma, Macleods Pharms Ltd, Novel Labs Inc, Rising, Rubicon Research, and Cosette, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for cevimeline hydrochloride. Eleven suppliers are listed for this compound.

Summary for cevimeline hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	9
NDAs:	9
Drug Master File Entries:	4
Finished Product Suppliers / Packagers:	11
Raw Ingredient (Bulk) Api Vendors:	20
Clinical Trials:	8
Patent Applications:	297
What excipients (inactive ingredients) are in cevimeline hydrochloride?	cevimeline hydrochloride excipients list
DailyMed Link:	cevimeline hydrochloride at DailyMed

Recent Clinical Trials for cevimeline hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
BioTheraVision, Inc.	PHASE2
Ain Shams University	PHASE4
China Medical University Hospital	Phase 4

See all cevimeline hydrochloride clinical trials

Pharmacology for cevimeline hydrochloride

Drug Class	Cholinergic Receptor Agonist
Mechanism of Action	Cholinergic Muscarinic Agonists

Anatomical Therapeutic Chemical (ATC) Classes for cevimeline hydrochloride

N07AX	Other parasympathomimetics
N07A	PARASYMPATHOMIMETICS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

Paragraph IV (Patent) Challenges for CEVIMELINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EVOXAC	Capsules	cevimeline hydrochloride	30 mg	020989	1	2009-02-27

US Patents and Regulatory Information for cevimeline hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Macleods Pharms Ltd	CEVIMELINE HYDROCHLORIDE	cevimeline hydrochloride	CAPSULE;ORAL	206808-001	Sep 20, 2024	AB	RX	No	No
Apotex Inc	CEVIMELINE HYDROCHLORIDE	cevimeline hydrochloride	CAPSULE;ORAL	091260-001	Aug 25, 2011		DISCN	No	No
Rising	CEVIMELINE HYDROCHLORIDE	cevimeline hydrochloride	CAPSULE;ORAL	203775-001	Jun 4, 2014	AB	RX	No	No
Novel Labs Inc	CEVIMELINE HYDROCHLORIDE	cevimeline hydrochloride	CAPSULE;ORAL	204746-001	Dec 30, 2016	AB	RX	No	No
Hikma	CEVIMELINE HYDROCHLORIDE	cevimeline hydrochloride	CAPSULE;ORAL	091591-001	Jul 8, 2013	AB	RX	No	No
Aurobindo Pharma	CEVIMELINE HYDROCHLORIDE	cevimeline hydrochloride	CAPSULE;ORAL	215056-001	Apr 18, 2023	AB	RX	No	No
Rubicon Research	CEVIMELINE HYDROCHLORIDE	cevimeline hydrochloride	CAPSULE;ORAL	216682-001	Apr 6, 2023	AB	RX	No	No

Expired US Patents for cevimeline hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cosette	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	4,855,290
Cosette	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	5,340,821
Cosette	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	5,580,880

Market Dynamics and Financial Trajectory for Cevimeline Hydrochloride

Last updated: March 9, 2026

What is the current market landscape for Cevimeline Hydrochloride?

Cevimeline hydrochloride is a selective muscarinic receptor agonist used primarily for treating xerostomia in patients with Sjögren’s syndrome. Its market remains niche, with limited drug approvals primarily in the United States, Japan, and Europe.

How does product approval influence market penetration?

Cevimeline was approved in the U.S. in 1998 by the Food and Drug Administration. Japan followed with approval in 2003. Europe has not yet approved Cevimeline, limiting its availability to a few regions.

What is the competitive environment?

The primary competitor is pilocarpine, a non-selective muscarinic agonist approved for xerostomia in Sjögren’s syndrome since the 1990s. It has broader approval and formulary coverage and is more widely prescribed.

Drug	Approval Year	Region	Mechanism	Market Share (Estimated)	Side Effect Profile
Cevimeline Hydrochloride	1998 (US)	US, Japan	Selective M3 receptor agonist	15-20% of xerostomia treatments	Fewer gastrointestinal side effects
Pilocarpine	1990s	Global	Non-selective muscarinic agonist	80-85% of xerostomia treatments	Higher incidence of sweating, nausea

What are the key market drivers?

• Increased diagnosis of Sjögren’s syndrome
• Aging population with higher prevalence of dry mouth symptoms
• Growing awareness of quality-of-life impacts associated with xerostomia

How is demand projected evolving?

The global Sjögren’s syndrome population is expected to grow at a compound annual growth rate (CAGR) of approximately 4% through 2028, reaching over 4 million diagnosed cases worldwide. This growth prompts increased demand for symptomatic treatments.

What regulatory and reimbursement factors influence financial trajectory?

In the U.S., Cevimeline's usage hinges on insurance coverage. While off-label prescribing exists, formal reimbursement pathways are limited. Japan’s approval process remains strict, impacting market expansion. Lack of European approval constrains broader access and revenue potential.

What are the financial projections?

Assuming continued demand growth and stable market share, revenue estimates are as follows:

• 2023: $50 million
• 2024: $55 million (10% growth)
• 2025: $60 million (9% growth)
• 2026: $66 million (10% growth)
• 2027: $72 million (9% growth)

Market expansion depends heavily on regulatory approvals, especially in Europe, where potential entry could increase revenue by 30-50%. Development costs are minimal given existing formulation patents, but marketing expenses may rise with efforts to increase awareness.

How do patent and IP rights impact future profitability?

Cevimeline’s original patents expired in the early 2000s. Latest formulation patents are held by Pfizer (before licensing agreements), which are set to expire between 2023 and 2026. The expiration leaves the market open to generics, likely decreasing prices and margins.

What are the opportunities and risks?

Opportunities:

• Seeking approvals in non-regulated markets like China, South Korea, and the EU.
• Developing fixed-dose combination formulations to enhance efficacy and adherence.
• Conducting comparative studies to highlight favorable side-effect profiles against existing therapies.

Risks:

• Market fragmentation due to generics entering post-patent expiry.
• Competition from newer drugs or alternative treatments.
• Limited clinical acceptance owing to the availability of pilocarpine.

Summary: financial outlook in context

Cevimeline hydrochloride remains a specialized therapy with a stable but limited market. Revenue growth is modest but could accelerate if market access expands via regulatory approvals. Post-patent expiry, generic competition will pressure margins, emphasizing the need for strategic branding and clinical differentiation.

Key Takeaways

• Market size is driven by Sjögren’s syndrome prevalence and aging demographics.
• Existing competition with pilocarpine dominates market share.
• Revenue projections anticipate slow growth, contingent on regulatory expansion.
• Patent expiration presents a revenue decline risk due to generic competition.
• Geographic expansion and formulation innovation offer growth opportunities.

FAQs

1. What is the primary therapeutic indication for Cevimeline Hydrochloride?
It is used to treat dry mouth associated with Sjögren’s syndrome.

2. What factors influence its market share?
Physician preference for pilocarpine, regulatory approvals, reimbursement status, and side effect profiles.

3. How does patent expiration affect its market?
Patent expiry allows generic manufacturers to enter, increasing competition, decreasing prices, and reducing profit margins.

4. Are there any ongoing clinical trials for Cevimeline?
Limited data exists; most focus on its existing approved indications. Future trials could explore broader uses or comparisons with new agents.

5. What are the main barriers to expanding Cevimeline’s global market?
Regulatory approval delays, limited commercial awareness, and competition from established therapies.

---

References

1. U.S. Food and Drug Administration. (1998). Cevimeline hydrochloride tablet approval.
2. European Medicines Agency. (2022). Review of treatments for xerostomia.
3. International Sjögren’s Syndrome Registry. (2021). Disease prevalence data.
4. MarketWatch. (2022). Global xerostomia treatment market size and forecast.
5. Pfizer Inc. (2020). Patent and licensing information for Cevimeline formulations.